Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be presented respectively as an oral presentation and a poster presentation, at the 2026 European Society for Medical Oncology Gynaecological Cancers (ESMO GC) Annual Congress, taking place in Copenhagen, Denmark from June 17–19, 2026.

Oral Presentation

Title: Bulumtatug Fuvedotin (BFv, 9MW2821), a nectin-4 antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: Updated results from a phase I/II study.

Abstract No.: 28RO

Presenter: Prof. Yang Huijuan, Fudan University Shanghai Cancer Center

Session Date and Time: 6/17/2026 2:45PM-4:10PM (local time)

Poster Presentation

Title: Preliminary results of Bulumtatug Fuvedotin (BFv, 9MW2821) in combined with Toripalimab in patients with recurrent or metastatic cervical cancer: A cohort from a Phase Ib/II Clinical Study.

Abstract No.: 36P

Principal Investigator:

Prof. Lou Hanmei, Zhejiang Cancer Hospital

Prof. Wang Yudong, International Peace Maternity and Child Health Hospital of China Welfare Institute

Session Date and Time: 6/18/2026 12:45PM-1:30PM (local time)